The proposed mechanisms are illustrated in Fig. 6E. To translate these findings into clinical applications, future studies can focus on validating CITED4 and BIRC2 as specific biomarkers for GEM-resistant PC patients. Here, BIRC2 is linked to pachyonychia congenita.